Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus anlotinib in advanced ESCC after failure of first-line immunotherapy
ChiCTR2500115664Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
QL1706anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500115664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115664.